Publications

HAX1 deficiency blocks granulopoiesis at the promyelocyte-to-myelocyte transition by impairing lipid droplet autophagy and fatty acid uptake; in vitro Kostmann disease model. PMID 42086536 verified.

GnT-IVa glycosyltransferase is upregulated as APL promyelocytes are driven by ATRA through the myelocyte differentiation program; N-glycan remodelling marks stage progression. PMID 42194104 verified.

Refined DMSO-based protocol for pushing HL60 cells through myelocyte-equivalent stages to neutrophil-like morphology and function; benchmark for in vitro differentiation assays. PMID 42329216 verified.

As HL60 cells move through the myelocyte-equivalent stage and toward the mature neutrophil, terminal galactose residues rise on the cell surface, marking a glycan remodelling event tied to the maturation program. PMID 42364919 verified.

Single-cell RNA-seq maps neutrophil subsets across tissues in autoimmune contexts; immature neutrophil populations including myelocyte-derived precursors show tissue-specific reprogramming. PMID 42784888 verified.

Deep learning model using co-occurrence feature maps achieves high accuracy in classifying myelocytes, metamyelocytes, band forms, and other immature leukocytes from peripheral blood smear images. PMID 40461529 verified.

Multi-omic map of the granulocyte line from progenitor to mature cell. Unreviewed.

Immature neutrophil gene programs associate with burn mortality and recur across other critical illnesses.

Neutrophil-intrinsic Vgll4 blocks STAT3/STAT5 transcription factor activity that would otherwise drive an immunosuppressive, pro-tumorigenic neutrophil state.

METTL7A-mediated m6A modification drives CXCR4hi neutrophil homing and NETosis; the epigenetic mark is acquired during the myeloid maturation program.

Neonatal neutrophils pass through stage-specific functional states that parallel the maturation stages from myelocyte onward; antimicrobial competence is acquired late.

TNF-alpha kills neutrophils via a c-Raf-MEK1/2-p38 MAPK-caspase cascade that is distinct from necroptosis; relevant to how mature neutrophils derived from the myelocyte meet their end.

Review of in vitro (HL60, iPSC-derived), ex vivo, and in vivo neutrophil models; discusses which maturation stages including the myelocyte are recapitulated by each platform and their limitations. PMID 42495811 verified.

In situ labeling of human marrow precursors; revises the textbook picture of which stages divide. Contradicts the classical placement of the myelocyte as the last mitotic stage.

Tumors drive emergency granulopoiesis and reprogram marrow neutrophils while they are still in the marrow.

HemaScribe and HemaScape map emergency myelopoiesis at single-cell resolution and find conserved activation modules.

The myelocyte and its child, the metamyelocyte, are immunosuppressive in human tumors rather than passive transit stages.

A reference atlas of normal human hematopoiesis used to place AML differentiation states.

Granulopoiesis about 50 percent and erythroblasts about 32 percent of the marrow differential; high interobserver variability for single stages.

Mass cytometry identifies a proliferative preNeu that gives rise to non-proliferating immature and mature neutrophils; preNeu requires C/EBP epsilon. Mouse data.

Cowland and Borregaard review granule formation as a process tied to maturation of neutrophil precursors in marrow.

Average circulating neutrophil lifespan of 5.4 days by in vivo labeling, at least 10 times longer than earlier ex vivo estimates.

A protein made at the myelocyte stage and packed into the secondary granules forming then.

Transcriptome across the maturation stages of human granulopoiesis.

Dancey and colleagues: mitotic pool (promyelocytes plus myelocytes) 2.11 x 10^9 cells/kg, postmitotic pool 5.59 x 10^9 cells/kg, transit time 6.60 days, production 0.85 x 10^9 cells/kg per day.

Bainton, Ullyot, and Farquhar: azurophil granules are made only in the promyelocyte, specific granules from the myelocyte onward. The ultrastructural basis of the staging.

Athens and colleagues: the first measurement of the circulating and marginal granulocyte pools in humans.